Oncogene-addicted Solid Tumors and Microbiome-lung Cancer As a Main Character: a Narrative Review

Background And Objective: Lung cancer stands as the main cause of cancer-related deaths worldwide. With the advent of immunotherapy and the discovery of targetable oncogenic driver genes, although prognosis has changed in the last few years, survival rates remain dismal for most patients. This emphasizes the urgent need for new strategies that could enhance treatment in precision medicine. The role of the microbiota in carcinogenesis constitutes an evolving landscape of which little is known. It has been suggested these microorganisms may influence in responses, resistance, and adverse effects to cancer treatments, particularly to immune checkpoint blockers. However, evidence on the impact of microbiota composition in oncogene-addicted tumors is lacking. This review aims to provide an overview of the relationship between microbiota, daily habits, the immune system, and oncogene-addicted tumors, focusing on lung cancer.

Methods: A PubMed and Google Scholar search from 2013 to 2024 was conducted. Relevant articles were reviewed in order to guide our research and generate hypothesis of clinical applicability.

Key Content And Findings: Microbiota is recognized to participate in immune reprogramming, fostering inflammatory, immunosuppressive, or anti-tumor responses. Therefore, identifying the microbiota that impact response to treatment and modulating its composition by interventions such as dietary modifications, probiotics or antibiotics, could potentially yield better outcomes for cancer patients. Additionally, targeted therapies that modulate molecular signaling pathways may impact both immunity and microbiota. Understanding this intricate interplay could unveil new therapeutic strategies.

Conclusions: By comprehending how microbiota may influence efficacy of targeted therapies, even though current evidence is scarce, we may generate interesting hypotheses that could improve clinical practice.

References

Wong B, Wang W, So W, Shin V, Wong W, Fung F . Epidermal growth factor and its receptor in chronic active gastritis and gastroduodenal ulcer before and after Helicobacter pylori eradication. Aliment Pharmacol Ther. 2001; 15(9):1459-65. DOI: 10.1046/j.1365-2036.2001.01051.x. View

Alkan Sen G, Oztas N, Degerli E, Can G, Turna H, Ozguroglu M . Effect of antibiotic treatment on immune checkpoint inhibitors efficacy in patients with advanced non-small cell lung cancer. Lung Cancer. 2023; 184:107347. DOI: 10.1016/j.lungcan.2023.107347. View

Jorgovanovic D, Song M, Wang L, Zhang Y . Roles of IFN-γ in tumor progression and regression: a review. Biomark Res. 2020; 8:49. PMC: 7526126. DOI: 10.1186/s40364-020-00228-x. View

Valero C, Lee M, Hoen D, Weiss K, Kelly D, Adusumilli P . Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun. 2021; 12(1):729. PMC: 7851155. DOI: 10.1038/s41467-021-20935-9. View

Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman A . Separating host and microbiome contributions to drug pharmacokinetics and toxicity. Science. 2019; 363(6427). PMC: 6533120. DOI: 10.1126/science.aat9931. View

Xu J, Yang M, Wang D, Zhang S, Yan S, Zhu Y . Alteration of the abundance of in the gut along the adenoma-carcinoma sequence. Oncol Lett. 2020; 20(4):106. PMC: 7439112. DOI: 10.3892/ol.2020.11967. View

Haldar K, George L, Wang Z, Mistry V, Ramsheh M, Free R . The sputum microbiome is distinct between COPD and health, independent of smoking history. Respir Res. 2020; 21(1):183. PMC: 7362436. DOI: 10.1186/s12931-020-01448-3. View

Mathieu E, Escribano-Vazquez U, Descamps D, Cherbuy C, Langella P, Riffault S . Paradigms of Lung Microbiota Functions in Health and Disease, Particularly, in Asthma. Front Physiol. 2018; 9:1168. PMC: 6110890. DOI: 10.3389/fphys.2018.01168. View

Secombe K, Van Sebille Y, Mayo B, Coller J, Gibson R, Bowen J . Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome. Integr Cancer Ther. 2020; 19:1534735420928493. PMC: 7273583. DOI: 10.1177/1534735420928493. View

10.

Gao Y, Shang Q, Li W, Guo W, Stojadinovic A, Mannion C . Antibiotics for cancer treatment: A double-edged sword. J Cancer. 2020; 11(17):5135-5149. PMC: 7378927. DOI: 10.7150/jca.47470. View

11.

Knippel R, Drewes J, Sears C . The Cancer Microbiome: Recent Highlights and Knowledge Gaps. Cancer Discov. 2021; 11(10):2378-2395. PMC: 8487941. DOI: 10.1158/2159-8290.CD-21-0324. View

12.

Roviello G, Iannone L, Bersanelli M, Mini E, Catalano M . The gut microbiome and efficacy of cancer immunotherapy. Pharmacol Ther. 2021; 231:107973. DOI: 10.1016/j.pharmthera.2021.107973. View

13.

Hahn A, Froerer C, VanAlstine S, Rathi N, Bailey E, Stenehjem D . Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma. Clin Genitourin Cancer. 2018; 16(5):365-368. DOI: 10.1016/j.clgc.2018.05.001. View

14.

Ramirez-Labrada A, Isla D, Artal A, Arias M, Rezusta A, Pardo J . The Influence of Lung Microbiota on Lung Carcinogenesis, Immunity, and Immunotherapy. Trends Cancer. 2020; 6(2):86-97. DOI: 10.1016/j.trecan.2019.12.007. View

15.

Zheng D, Liwinski T, Elinav E . Interaction between microbiota and immunity in health and disease. Cell Res. 2020; 30(6):492-506. PMC: 7264227. DOI: 10.1038/s41422-020-0332-7. View

16.

Liu X, Cheng Y, Zang D, Zhang M, Li X, Liu D . The Role of Gut Microbiota in Lung Cancer: From Carcinogenesis to Immunotherapy. Front Oncol. 2021; 11:720842. PMC: 8417127. DOI: 10.3389/fonc.2021.720842. View

17.

Owaga E, Hsieh R, Mugendi B, Masuku S, Shih C, Chang J . Th17 Cells as Potential Probiotic Therapeutic Targets in Inflammatory Bowel Diseases. Int J Mol Sci. 2015; 16(9):20841-58. PMC: 4613231. DOI: 10.3390/ijms160920841. View

18.

Dong S, Han Y, Wu J, Zeng C, Zhu K, Chen X . Distribution of Microbiota in Fine Particulate Matter Particles in Guangzhou, China. Biomed Environ Sci. 2020; 33(5):306-314. DOI: 10.3967/bes2020.042. View

19.

Kim J, Lee H . Potential Role of the Gut Microbiome In Colorectal Cancer Progression. Front Immunol. 2022; 12:807648. PMC: 8777015. DOI: 10.3389/fimmu.2021.807648. View

20.

Patangia D, Anthony Ryan C, Dempsey E, Ross R, Stanton C . Impact of antibiotics on the human microbiome and consequences for host health. Microbiologyopen. 2022; 11(1):e1260. PMC: 8756738. DOI: 10.1002/mbo3.1260. View